Research graph
References from Case Report: Exceptional survival with immunotherapy in a patient with EGFR exon 20 insertion (p.S768_D770dup) and high PD-L1 expression. Local targets link to admitted publications; unresolved targets remain external evidence.
Lazertinib versus osimertinib in previously untreated EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA
10.1016/j.jtho.2025.06.030 · 2025 · External reference
EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins
10.1016/j.ctrv.2020.102105 · 2020 · External reference
Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity
10.1073/pnas.2417144121 · 2024 · External reference
New promises and challenges in the treatment of advanced non-small-cell lung cancer
10.1016/s0140-6736(24)01029-8 · 2024 · External reference
Research progress in immunotherapy of NSCLC with EGFR-sensitive mutations
10.3727/096504022x16462176651719 · 2022 · External reference
Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC
10.1016/j.jtho.2023.11.020 · 2024 · External reference
Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
10.1158/2159-8290.cd-21-1615 · 2022 · External reference
Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
10.1016/j.annonc.2021.08.1815 · 2021 · External reference
IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain
10.1016/j.jtho.2021.09.014 · 2022 · External reference
Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722
10.1200/jco.23.01017 · 2024 · External reference
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
10.1136/jitc-2023-006887 · 2023 · External reference
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
10.3389/fimmu.2023.1161718 · 2023 · External reference
Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-mutant NSCLC
10.3389/fonc.2021.671228 · 2021 · External reference
Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
10.21037/tlcr-23-167 · 2023 · External reference
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
10.1016/j.esmoop.2021.100253 · 2021 · External reference
Structure-based classification predicts drug response in EGFR-mutant NSCLC
10.1038/s41586-021-03898-1 · 2021 · External reference
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint inhibitors in non-small cell lung cancer
10.1200/jco.2018.36.15_suppl.9052 · 2018 · External reference
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations
10.3390/genes12050679 · 2021 · External reference
